Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.06, $0.20 worse than the analyst estimate of $4.26. Revenue for the quarter came in at $2.77 billion versus the consensus estimate of $2.86 billion.

GUIDANCE:

Vertex Pharma sees FY2025 revenue of $11.85-12 billion, versus the consensus of $11.982 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.